Quartz·1 min read·medium
AbCellera stock surges after menopause drug shows strong trial results
✦AI Summary
AbCellera's stock price rose following positive clinical trial results for its menopause drug, ABCL635. The drug demonstrated an 83% reduction in hot flash frequency after four weeks compared to a 33% reduction for the placebo.
A single dose of ABCL635 cut hot flash frequency by 83% after four weeks, compared with 33% for placebo
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in